Calciphylaxis as a Rare Complication Associated with Pemigatinib Treatment—A Case Report.
Simple Summary: Pemigatinib, an FGFR2 inhibitor, is used to treat FGFR2-altered cholangiocarcinoma but may lead to rare, serious side effects. We report a 43-year-old woman with metastatic intrahepatic cholangiocarcinoma who developed calciphylaxis—a rare, life-threatening condition involving vascul...
| Publicado en: | Current Oncology Vol. 33; no. 6; pp. 360 - 368 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Jun2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |